Lead Product(s) : OMTX705,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : CDTI
Deal Size : $25.6 million
Deal Type : Financing
Oncomatryx Raises €25 Million to Foster OMTX705 Clinical Trials
Details : The proceeds will be used to fund Phase Ib-II clinical trials of OMTX705, a first-in-class, novel ADC targeting fibroblast activation protein (FAP), to treat metastatic solid tumors.
Product Name : OMTX705
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
January 27, 2025
Lead Product(s) : OMTX705,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : CDTI
Deal Size : $25.6 million
Deal Type : Financing
Lead Product(s) : Iadademstat,Azacitidine,Venetoclax
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ORYZON Doses First Patient in Phase I Study of Iadademstat in Myelodysplastic Syndrome
Details : ORY-1001 (iadademstat) is a highly selective inhibitor of the epigenetic enzyme LSD1. It is being investigated in patients with myelodysplastic syndrome.
Product Name : ORY-1001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 23, 2025
Lead Product(s) : Iadademstat,Azacitidine,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Iadademstat,Azacitidine,Venetoclax
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ORYZON Doses First Patient in Iadademstat- Venetoclax Trial for AML
Details : ORY-1001 (iadademstat) is a highly selective inhibitor of the epigenetic enzyme LSD1. It is being investigated in combination with venetoclax & azacitidine in patients with acute myeloid leukemia.
Product Name : ORY-1001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 13, 2025
Lead Product(s) : Iadademstat,Azacitidine,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Iadademstat,Azacitidine,Venetoclax
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ORYZON Doses First Patient in Phase Ib Study of Iadademstat for Acute Myeloid Leukemia
Details : ORY-1001 (iadademstat) is a highly selective inhibitor of the epigenetic enzyme LSD1. It is being investigated in combination with venetoclax & azacitidine in patients with acute myeloid leukemia.
Product Name : ORY-1001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 09, 2024
Lead Product(s) : Iadademstat,Azacitidine,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Iadademstat,Gilteritinib Fumarate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ORY-1001 (iadademstat) is a highly selective inhibitor of the epigenetic enzyme LSD1 with powerful differentiating effect in hematologic cancer. It is being investigated in with gilteritinib for relapsed/refractory AML harboring a FMS-like tyrosine kinas...
Product Name : ORY-1001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 15, 2023
Lead Product(s) : Iadademstat,Gilteritinib Fumarate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PharmaMar Initiates First Human Clinical Trial of A New Molecule, PM534, For Cancer Patients
Details : PM534, a novel marine-derived anti-tumor compound, has been tested in the laboratory, both in cell cultures and in animals. In both cases, PM534 showed relevant antitumor activity in a wide variety of tumor types, including those with resistance to other...
Product Name : PM534
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 30, 2022
Lead Product(s) : VCN-01,Gemcitabine,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Theriva Biologics
Deal Size : $4.7 million
Deal Type : Acquisition
Synthetic Biologics Completes Acquisition of VCN Biosciences
Details : The acquisition transforms Synthetic Biologics’ pipeline with the addition of VCN's lead clinical-stage drug candidate, VCN-01, as well as preclinical stage VCN-11, both of which are next-generation OVs in development for the treatment of cancers with ...
Product Name : VCN-01
Product Type : Microorganism
Upfront Cash : Undisclosed
November 03, 2022
Lead Product(s) : VCN-01,Gemcitabine,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Theriva Biologics
Deal Size : $4.7 million
Deal Type : Acquisition
Lead Product(s) : VCN-01,Paclitaxel,Gemcitabine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Theriva Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VCN Biosciences lead product, VCN-01, is a oncolytic adenovirus with unique characteristics being studied in clinical trials for cancers for which there is no cure, including pancreatic carcinoma and retinoblastoma.
Product Name : VCN-01
Product Type : Microorganism
Upfront Cash : Inapplicable
August 02, 2022
Lead Product(s) : VCN-01,Paclitaxel,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Theriva Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VCN-01,Gemcitabine,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Grifols International
Deal Size : $77.4 million
Deal Type : Acquisition
Details : VCN has the rights to four exclusive patents for proprietary technologies, including VCN-01, as well as technologies developed in collaboration with the Virotherapy Group of the Catalan Institute of Oncology (ICO-IDIBELL), with a number of additional pat...
Product Name : VCN-01
Product Type : Microorganism
Upfront Cash : $4.7 million
December 14, 2021
Lead Product(s) : VCN-01,Gemcitabine,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Grifols International
Deal Size : $77.4 million
Deal Type : Acquisition
Lead Product(s) : Lurbinectedin
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Immedica Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Details : Immedica gets an exclusive distribution and marketing right of the anti-tumor drug lurbinectedin for territories that include the UK, Ireland, the Nordic countries, Middle East and North Africa.
Product Name : Zepzelca
Product Type : Cytotoxic Drug
Upfront Cash : $2.1 million
April 29, 2020
Lead Product(s) : Lurbinectedin
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Immedica Pharma
Deal Size : Undisclosed
Deal Type : Agreement